Ms. Ailsa Bosworth

• 
  www.theherald.co.uk/news/health/display.var.2403926.0.6 - [Cached Version]
  Published on: 7/20/2008    Last Visited: 7/20/2008  

  Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said the move, combined with a Nice decision in April to reject the drug abatacept, meant effective therapies had been cut from five to two.
  
  She added: "This decision is another nail in the coffin for the treatment of RA in England and Wales.

• 
  www.itfmweek.com/News.aspx?id=115750315&m=pharma - [Cached Version]
  Published on: 10/6/2008    Last Visited: 3/22/2008  

  Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said: "Today's data offer encouragement to people who cannot control their disease with current treatments."
  
  (c) 2008 Yorkshire Post.Provided by ProQuest Information and Learning.All rights Reserved.

• 
  www.prweek.com/uk/sectors/healthcare/article/834173/on- - [Cached Version]
  Published on: 7/31/2008    Last Visited: 7/31/2008  

  The National Rheumatoid Arthritis Society's chief executive Ailsa Bosworth said: 'This decision is another nail in the coffin for the treatment of rheumatoid arthritis.

• 
  www.rheumatoid.org.uk/article.php?article_id=535 - [Cached Version]
  Published on: 7/21/2008    Last Visited: 8/2/2008  

  Ailsa Bosworth, Chief Executive of the National Rheumatoid Arthritis Society, comments:
  ...
  Ailsa continues:
  
  "NICE is systematically taking away clinically effective and proven treatments from patients and giving them just one roll of the dice when it comes to Anti-TNF treatment."
  
  This decision flies in the face of the recommendations in Dame Carol Black's recent report - Working for a healthier tomorrow - about supporting people to remain in work and the Department of Work and Pensions' aspirations to have 80% of working age population in work by 2010.1
  
  Ailsa, an RA sufferer herself for 28 years and who is on her third anti-TNF treatment which enables her to work 50-60 hours a week and run an organisation employing 14 people, is concerned that the views of patients have been totally ignored by NICE:

• 
  www.rheumatoid.org.uk/article.php?article_id=527 - [Cached Version]
  Published on: 6/2/2008    Last Visited: 8/2/2008  

  Ailsa Bosworth, Chief Executive of the National Rheumatoid Arthritis Society, comments:

• 
  www.rheumatoid.org.uk/article.php?article_id=509 - [Cached Version]
  Published on: 4/29/2008    Last Visited: 8/2/2008  

  Ailsa Bosworth, Chief Executive of the National Rheumatoid Arthritis Society, comments:
  ...
  Ailsa says:
  ...
  Ailsa concludes:

• 
  www.catalyze.co.uk/?id=280 - [Cached Version]
  Published on: 10/6/2008    Last Visited: 8/11/2008  

  Ailsa Bosworth, Chief Executive
  ...
  Ailsa Bosworth, Chief Executive and Founder

• 
  piercing.org.uk/health/breakthrough-arthritis-pain-reli - [Cached Version]
  Published on: 10/6/2008    Last Visited: 8/5/2007  

  Ailsa Bosworth, chief executive of NRAS, said: "This is extremely bad news for people living with severe rheumatoid arthritis in the UK and a potential step backwards in the management of the condition if this decision is not reversed.

• 
  www.rheumatoid.org.uk/article.php?article_id=508 - [Cached Version]
  Published on: 4/23/2008    Last Visited: 8/2/2008  

  Ailsa Bosworth, Chief Executive of NRAS, comments:
  ...
  Ailsa concludes:

• 
  www.telegraph.co.uk/news/newstopics/politics/health/230 - [Cached Version]
  Published on: 7/21/2008    Last Visited: 7/21/2008  

  Ailsa Bosworth, Chief Executive of the National Rheumatoid Arthritis Society, said: "This decision is another nail in the coffin for the treatment of rheumatoid arthritis in England and Wales.
  ...
  You wrote that Ailsa Bosworth, Chief Executive of the National Rheumatoid Arthritis Society, said: "This decision is another nail in the coffin for the treatment of rheumatoid arthritis in England and Wales".

Page:  1 2 3 4 5